بكالوريوس / Bachelor's

Study Title Prevalence of Vitiligo Among Patients with Type 1 Diabetes Mellitus Attending Al-Jemaih Diabetic Centre Study Aim To determine the prevalence of vitiligo among patients with type 1 diabetes mellitus attending Al-Jemaih Diabetic Centre. Methodology Study Design: A descriptive cross-sectional study. Study Setting: The study will be conducted at Al-Jemaih Diabetic Centre. Study Period: The study will be conducted from September to December 2026 Study Population: The study population will comprise patients diagnosed with type 1 diabetes mellitus who attend Al-Jemaih Diabetic Centre during the study period. Sampling Technique: Consecutive sampling Sample Size: The study will include 40 patients with type 1 diabetes mellitus. Data Collection Methods: Data will be collected using a structured interviewer-administered questionnaire and clinical assessment for vitiligo. Data Analysis: Using SPSS

Participants' confidentiality will be maintained throughout the study. Each participant will be assigned a unique study identification code, and names and other direct identifiers will not be included in the research dataset. Data will be stored securely and accessed only by the research team. Electronic data will be password-protected, and paper records will be kept in a secure location. The collected data will be used solely for research purposes, and results will be reported in aggregate form without identifying individual participants.

This study is expected to involve minimal risk to participants. Potential risks include mild discomfort or embarrassment during the interview or clinical examination. There are no anticipated physical risks beyond those associated with a routine clinical examination. Participants may decline to answer any question or withdraw from the study at any time without affecting their medical care. Confidentiality will be maintained throughout the study.

Participants may not receive any direct personal benefit from taking part in this study. However, the findings are expected to provide information on the prevalence of vitiligo among patients with type 1 diabetes mellitus attending Al-Jemaih Diabetic Centre.